FDA
-
-
-
-
-
-
-
Barclays Starts Alpha Tau Medical Ltd. (DRTS) at Overweight
-
-
-
-
-
-
-
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
-
-
-
-
-
-
-
Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
-
-
-
-
-
-
-
Alpha Tau Medical (DRTS) Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT in Recurrent Cutaneous SCC
-
-
-
327,814 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

